Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.38 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29428770 | 1.00 | CYP2C19 (0.44) | CYP2C19METPKMHTR6KMT2A | |
| SCHEMBL21490894 | 0.89 | HTR6 (0.40) | CYP2C19METPKMHTR6KMT2A | |
| SCHEMBL23120015 | 0.89 | L3MBTL1 (0.46) | METPKMHTR6KMT2AMEN1 | |
| SCHEMBL1669689 | 0.85 | CYP2C19 (0.44) | CYP2C19METHTR6KMT2AMEN1 | |
| SCHEMBL29428833 | 0.85 | CYP2C19 (0.44) | CYP2C19METPKMHTR6KMT2A | |
| SCHEMBL25190824 | 0.85 | CYP2C19 (0.44) | CYP2C19METPKMHTR6KMT2A | |
| SCHEMBL17628727 | 0.85 | CYP2C19 (0.44) | CYP2C19METHTR6KMT2AMEN1 | |
| SCHEMBL28735217 | 0.85 | HTR6 (0.46) | CYP2C19METPKMHTR6KMT2A | |
| SCHEMBL2354234 | 0.83 | GSK3A (0.42) | CYP2C19METHTR6KMT2AMEN1 | |
| SCHEMBL24166017 | 0.83 | CYP2C19 (0.42) | CYP2C19METHTR6KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20250320212-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORP (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4620469-A2 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12390451-B2 | Small molecule inhibitor of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-19 | — | — | US | disclosed |
| WO-2025111464-A1 | JAK2 V617F INHIBITORS AND METHODS OF USE THEREOF | RAYTHERA, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4175719-B1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORP (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250122170-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2025-04-17 | — | — | US | disclosed |
| US-20250092044-A1 | Kinase Inhibitors | INCYTE CORPORATION | 2025-03-20 | — | — | US | disclosed |
| US-20250092043-A1 | Kinase Inhibitors and Degraders | INCYTE CORPORATION | 2025-03-20 | — | — | US | disclosed |
| EP-4493558-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2025-01-22 | — | — | EP | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| WO-2013007765-A1 | FUSED TRICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF JANUS KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013007765-A1 | FUSED TRICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF JANUS KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| EP-2523957-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | disclosed |
| WO-2012085176-A1 | TRICYCLIC PYRAZINONE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JANUS KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085176-A1 | TRICYCLIC PYRAZINONE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JANUS KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092044-A1 | Kinase Inhibitors | JAK2, JAK1, JAK3 | CYP2C19 3207/4885MET 790/4885PKM 737/4885 |
| US-20250320212-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | CYP2C19 1141/4885MET 1109/4885PKM 1564/4885 |
| US-12390451-B2 | Small molecule inhibitor of the JAK family of kinases | JAK2, JAK1, JAK3 | CYP2C19 4303/4885MET 1057/4885PKM 2143/4885 |
| US-20250122170-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | CYP2C19 1141/4885MET 1109/4885PKM 1564/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | CYP2C19 121/4885MET 2642/4885PKM 1313/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | CYP2C19 30/4885MET 208/4885PKM 1871/4885 |
| US-20250092043-A1 | Kinase Inhibitors and Degraders | JAK2, JAK1, JAK3 | CYP2C19 2641/4885MET 530/4885PKM 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.